# [Project Name] ST-to-Target Assessment Report
**Input Data:** Spatial Transcriptomics (ST) derived Ligand-Receptor Pairs
**Target Disease Focus:** [e.g., Alzheimer's Disease / Breast Cancer / Pan-disease]

## 1. Executive Summary
This report evaluates [N] ligand-receptor (L-R) interactions identified via spatial transcriptomics, demonstrating significant spatial colocalization. Using a multi-stage, database-driven automated pipeline, we prioritize targets based on universal druggability, disease-specific genetic validation, and clinical evidence.

**Top Priority Featured Candidates:** [Gene A], [Gene B], [Gene C]
* **[Gene A]:** Strong Open Targets association score with optimal safety profile (DrugBank). Validated therapeutic target with clinical evidence.
* **[Gene B]:** High spatial interaction score; confirmed STRING PPI interaction with robust GWAS support.
* **[Gene C]:** Exploratory target with strong biological plausibility and emerging clinical trial activity.

**Novel Discoveries:** [Gene D], [Gene E]
* **[Gene D]:** Novel target with no existing drugs -- discovered through ST colocalization and Census cross-validation. Tier 1 (GWAS support).
* **[Gene E]:** Novel candidate with compelling biological plausibility from pathway analysis. Tier 2 (ST-only evidence).

---

## 2. Pan-Disease Target Druggability Matrix (Pipeline Stage 1 & 2)

*This matrix is populated via **Open Targets (OT)**, **GWAS Catalog**, **Cellxgene Census**, and **Ensembl VEP**. It serves as the primary filter to identify Featured and Novel Candidates.*

| Rank | L-R Pair | Track | OT Association Score | Max Clinical Phase | ST Colocalization Score | Genetic Flag (VEP/GWAS) | Tractability (OT) |
|---|---|---|---|---|---|---|---|
| 1 | **[Ligand 1 - Receptor 1]** | **[FEATURED]** | 0.85 | Phase 3 | High | Pathogenic Driver (VEP) | Small Molecule |
| 2 | **[Ligand 2 - Receptor 2]** | **[FEATURED]** | 0.72 | Phase 1 | Medium | eQTL confirmed | Antibody |
| 3 | **[Ligand 3 - Receptor 3]** | **[NOVEL]** | 0.15 | Pre-clinical | High | GWAS suggestive | Predicted |
| ... | ... | | ... | ... | ... | ... | ... |

*Note: [FEATURED] and [NOVEL] candidates proceed to Stage 3 Deep Dives.*

---

## 3. [FEATURED] Candidate Deep Dives (Pipeline Stage 3)

*This section executes conditional deep-dive queries (**DrugBank/ChEMBL, PubMed API**) for Featured candidates with existing drug evidence.*

### [FEATURED] [Target Gene Name] -- Priority: HIGH

**A. Clinical & Safety Profile (Stage 3)**
* **Known Drugs (DrugBank/ChEMBL):** [Extract active ingredients/drugs targeting this receptor. Source field indicates DrugBank or ChEMBL.]
* **Toxicity & ADMET (DrugBank):** [Extract key warnings, e.g., Hepatotoxicity risk]
* **Latest Clinical Insights (PubMed -- *Conditional Run*):** [Triggered if Max Phase >= 2. Extract recent trial adverse events or efficacy summaries from abstract NLP].

**B. Biological Context & Pathway (Stage 1 Validation)**
* **STRING PPI Validation:** [Confirmed / Not Confirmed - Score: 0.8]
* **Primary Pathway (KEGG/Reactome):** [e.g., Cytokine-cytokine receptor interaction (hsa04060)]
* **Census Cross-Validation:** [Z-test result: target vs rest cell types]

**C. Rubric Assessment Summary**
* **Validated Track:** existing_drug_evidence=[score], clinical_trial_activity=[score], mechanism_relevance=[score], safety_profile=[score]
* **Exploratory Track:** gwas_genetic_support=[score], tractability=[score], biological_plausibility=[score], novelty_opportunity=[score]
* **Classification:** [validated_target | exploratory_target]
* **Priority:** [high | medium | low]

---
*(Repeat Deep Dive section for other Featured Candidates)*
---

## 4. [NOVEL] Candidate Deep Dives (Pipeline Stage 3)

*This section covers newly discovered targets with NO existing drug evidence, identified through ST CCI analysis.*

### [NOVEL] [Target Gene Name] -- Tier: [1|2] | Priority: [PRIORITY]

**A. Why This Is Novel**
* No existing drugs targeting this gene in DrugBank or ChEMBL
* Discovery pathway: ST colocalization -> Census validation -> pathway analysis
* Novel Tier: [Tier 1: GWAS/tractability support | Tier 2: ST-only evidence]

**B. Biological Evidence (Stage 1)**
* **STRING PPI:** [Score and interaction status]
* **Pathway:** [KEGG/Reactome shared pathways between ligand and receptor]
* **Census Cross-Validation:** [Z-test result]

**C. Exploratory Evidence (Stage 2)**
* **GWAS Findings:** [Gene-trait associations, disease-specific hits]
* **Tractability:** [OpenTargets tractability assessment]
* **Biological Plausibility:** [Multi-evidence summary]

**D. Drug Development Potential (Stage 3)**
* **DrugBank/ChEMBL:** [Expected: no direct matches for truly novel targets]
* **Tractability Assessment:** [Small molecule / Antibody / Other modality potential]

**E. Recommendation**
* [Recommended next steps for novel target validation]

---
*(Repeat for other Novel Candidates)*
---

## 5. Pipeline Execution Summary & Recommendations
* **Total Initial L-R Pairs:** [Number]
* **Featured Candidates Selected:** [Number] (existing drug evidence >= 1)
* **Novel Candidates Selected:** [Number] (no existing drugs, ranked by exploratory score)
* **API Call Summary:** Open Targets ([N] calls), GWAS ([N] calls), DrugBank/ChEMBL ([N] calls), PubMed ([N] conditional calls).
* **Recommendation Categories:**
  * **Validated Targets:** Ready for drug development consideration [FEATURED validated_target]
  * **Exploratory Targets:** Warrant further investigation [FEATURED exploratory]
  * **Novel Discoveries:** New targets from ST analysis [NOVEL]
  * **Insufficient Evidence:** Require additional data

# End of Report